Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Katherine Kargus"'
Autor:
David M. Hyman, Lynette M. Sholl, Katherine Kargus, Hebert Alberto Vargas, Ann E. Sisk, Elio Adib, James J. Harding, Solida Pruitt-Thompson, Krinio Giannikou, Jennifer Hedglin, Martin H. Voss, Khanh T. Do, Ketki Bhushan, Matthew I. Milstein, David J. Kwiatkowski, Gopa Iyer, Geoffrey I. Shapiro, Junko Tsuji, Katarzyna Klonowska
Publikováno v:
Clinical Cancer Research. 27:3845-3853
Purpose:This was a multicenter, histology-agnostic, single-arm prospective phase II trial of therapeutic activity of everolimus, an oral mTORC1 inhibitor, in patients with advanced solid tumors that harbored TSC1/TSC2 or MTOR mutations.Patients and M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c7b5ee82e0c265db1a5c400c7c7ceb6
https://doi.org/10.1158/1078-0432.ccr-20-4548
https://doi.org/10.1158/1078-0432.ccr-20-4548
Autor:
Neil H. Segal, David M. Hyman, Katherine Kargus, Alison M. Schram, Jessica Flynn, Komal Jhaveri, Mrinal M. Gounder, Danny N. Khalil, Alexander Drilon, Stefan Hamaway, Mary Kate Kasler, Dazhi Liu, Sandy Badson, Natalie M. Blauvelt, Maya Gambarin-Gelwan, Sebastian Mondaca, Bob T. Li, Marinela Capanu, Margaret K. Callahan, James J. Harding
Publikováno v:
Cancer
Background Data on drug-induced liver injury (DILI) and acute liver failure (ALF) in modern phase 1 oncology trials are limited, specifically with respect to the incidence and resolution of DILI and the safety of drug rechallenge. Methods This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8556f1de6e947491d06cde4cca090389
https://pubmed.ncbi.nlm.nih.gov/32809222
https://pubmed.ncbi.nlm.nih.gov/32809222
Autor:
Thu Oanh Dang, Yat Yee So-Kwan, David M. Hyman, Stephen Harnicar, Katherine Kargus, Lauren A Evans, Dazhi Liu
Publikováno v:
Journal of Clinical Oncology. 35:e18228-e18228
e18228 Background: Early phase clinical trials have broadened treatment options for patients with cancer. Expert management of these new therapies is essential to positive patient outcomes. At Memorial Sloan Kettering Cancer Center, the Developmental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32b0c4c38ae9a1bb1479484e9d3bac5f
https://doi.org/10.1200/jco.2017.35.15_suppl.e18228
https://doi.org/10.1200/jco.2017.35.15_suppl.e18228
Autor:
John F. Gerecitano, Gary K Schwartz, Richard Carvajal, Matthew Fury, Jason Konner, David M. Hyman, Mrinal Gounder, Devika Gajria, Jerrold Teitcher, Zhigang Zhang, Craig H. Moskowitz, Jan H Beumer, Alice Chen, Richard F Little, Fallon France, Juho Whang, Jennifer Winkelman, Megan Stasi, Corey Russell, Naomi Cazeau, Katherine Kargus, Andrew D. Zelenetz
Publikováno v:
Blood. 122:4366-4366
Background PARP is overexpressed in many malignancies, and can protect tumor cells from genetic damage. The PARP inhibitor ABT-888 (A) enhances the cytotoxicity of several alkylating agents. Since bendamustine (B) is an alkylator with promising clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5bfae962d93447846092dd4db2ece4e
https://doi.org/10.1182/blood.v122.21.4366.4366
https://doi.org/10.1182/blood.v122.21.4366.4366
Autor:
Rustgi, Naryan, Maria, Ann, Toumbacaris, Nicolas, Zhao, HuiYong, Kargus, Katherine, Bryant, Morgan, Waksmundzki, Alexandra, Aricescu, Ilinca, Lefkowitz, Robert A, Li, Bob T, Chou, Joanne, Capanu, Marinela, Stanchina, Elisa de, Misale, Sandra, Shia, Jinru, Yaeger, Rona
Publikováno v:
Oncologist; Jan2024, Vol. 29 Issue 1, p15-24, 10p
Publikováno v:
Clinical Trials Week; 11/14/2023, p525-525, 1p